Market Overview
The global RNA interference (RNAi) technology market size was worth US$ 1,044.8 million in 2020 and is estimated to reach US$ 2,236.2 million by 2028, growing at a CAGR of 10.3% during the forecast period (2021-2028)
RNA interference (RNAi) is a technology used to treat cancer and other diseases by post-transcriptional silencing of genes by small nucleic acid fragments. This technology helps provide target specificity to proteins lacking the enzymatic pocket necessary for binding
RNAi has a significant impact on the speed, ease, and specificity with which the loss of gene function analysis can be made in mammalian cells and animal models. This technology can validate the target genes and functionally assess relevant disease genes. Hence, leading to the development of effective therapeutics
The global RNAi technology market growth is driven by several factors, such as rising genetic and metabolic disorders, increasing molecular diagnostics applications, cancer, and growing research & development activities for drug discovery
Market Dynamics
RNAi is most likely to have the biggest impact as a therapeutic tool in two main clinical areas: cancer and infectious disease, but it also has the potential to be used to treat other diseases, such as some dominant genetic diseases
As of 2018, around XX million people on earth are living with rare disorders. Approximately XX% of these rare disorders are genetic in nature, and XX% of them do not even have one FDA-approved treatment
With the incorporation of RNAi techniques in molecular diagnostics and personalized medicine, cancer diagnosis and treatment are currently undergoing a shift. Because high-throughput techniques for identifying changed cellular components and metabolites are now available, RNAi techniques can be used in a variety of cancer diagnoses and targeting approaches
MicroRNAs (miRNA) or small interfering RNAs (siRNA) can be utilized for diagnostic purposes. The commercial availability of siRNAs that can silence virtually any gene in the human genome is dramatically increasing the pace of molecular diagnosis and biomedical research. Thus, increasing the application of RNAi in molecular diagnosis and its viability as a therapeutic technique is expected to drive the growth of the market
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/rnai-technology-market
Industry Forces
RNAi-therapy researchers know that many existing medicines received approval only after the technologies that underpin them took a serious tumble. Gene therapy, for example, has a troubled history, in which the death of a teenage boy during a clinical trial in 1999 derailed the field for years; the first such product to receive approval from the US Food and Drug Administration (FDA), voretigene neparvovec (Luxturna), developed by Spark Therapeutics in Philadelphia, Pennsylvania, to treat a rare form of vision impairment, did not receive approval until 2017.
The RNAi technology is classified into Interfering RNAs (siRNA) and MicroRNA (miRNA). RNA interference (RNAi) is a natural cellular process that regulates gene expression by a highly precise mechanism of sequence-directed gene silencing at the translation stage by degrading specific messenger RNAs or blocking translation.
COVID 19 Impact Analysis
COVID 19 are positive single-strand RNA with 32–46% G + C content. They have the biggest genome size among all known RNA viruses. According to recent reports, the ORF portion of the SARS-CoV-2 genome has a lower CG dinucleotide percentage than other coronaviruses, so ORF RNA translation is highly efficient.
While entry pathways and cleavage patterns seem similar in SARS-CoV and SARS-CoV-2, some minor differences in the spike protein of SARS-CoV-2 have been noted, offering an explanation for the rapid spread of COVID-19.
Both COVID 19 display an identical furin-like S2ʹ cleavage site, containing basic residues necessary for furin mediated fusion, but SARS-CoV-2 has an SPRR insertion at the S1/S2 boundary cleavage site of the S protein.
As a result of this insertion, SARS-CoV-2 displays a significantly higher furin score than SARS-CoV attributing to more efficient cleavage of the spike protein of SARS-CoV-2 that ultimately increases the viruses pathogenicity.
Market Segmentation
- By Technology Type
- By Application
- By Region
By Technology Type – Interfering RNAs (siRNA)
RNA interference is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression.
Interfering RNAs (siRNA) is a fundamental pathway in eukaryotic cells by which sequence-specific small interfering RNA (siRNA) is able to silence genes through the destruction of complementary mRNA. RNAi is an important therapeutic tool that can be used to silence aberrant endogenous genes or to knockdown genes essential to the proliferation of infectious organisms.
The advantages of RNAi in cancer therapy are effective suppression of the growth of advanced-stage tumors, relatively low cost, and high specificity. RNAi can inhibit multiple genes of various pathways simultaneously, which could be conducive to reducing drug resistance. For example, Guan et al. found that inhibition of SH3GL1 using siRNA could reverse MDR by decreasing P-glycoprotein expression via the EGFR/ERK/AP-1 pathway.
With the development of more effective delivery based systems, RNAi could also be used to develop personalized drugs for specific patients as adjuvants to chemotherapy.
RNAi has become widely used as a tool to modulate gene expression. A vast amount of experimental data has been accumulated, which allows design and validation of RNAi prediction models.
Geographical Analysis – North America
North America is the largest regional market in the global RNAi technology market, dominating in terms of research, development, innovation and commercial penetration as a drug development technology
The discovery of RNA interference by American biologists Craig Mello and Andrew Fire and the subsequent awarding of Nobel Prize in 2006 marked the shift of medical interest towards this technology in the region. Emphasis has been laid on its importance in drug development and pathology.
Led by the U.S., the North America RNAi technology market valued USD XX million in 2022, which is 10.6% of the revenue generated globally. The market is estimated to further reach USD XX million by 2029, growing at a CAGR of 10.6% during the forecast period (2022-2029).
Competitive Analysis
The global RNAi technology market is highly fragmented with a large number of global & local players. Some of the market’s major players include Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Quark Pharmaceuticals, Inc., Silence Therapeutics, and Arrowhead Pharmaceuticals Inc. among others
The key players are adopting various growth strategies such as expansion, mergers & acquisitions, partnerships, product launches, and collaborations, contributing to the growth of the RNAi technology market globally. For instance,
In January 2021, Atalanta Therapeutics launched with $110 million to pioneer RNAi therapeutics for neurodegenerative diseases. It announced strategic collaborations with Biogen, Genentech to develop RNAi therapeutics for neurodegenerative diseases.
Trending Reports
DNA Methylation Sequencing Market
Spatial Genomics & Transcriptomics Market
About Us:
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.
Media Contact:
Name: Sai Kiran
Company: DataM Intelligence
Contact No: +1 8774414866
Email us: info@datamintelligence.com